CD8A and neoplasm: c-DC1s are known to have a central function in the TME by leveraging their ability to cross-present (cross-priming) tumor-associated antigens (TAAs), eliciting a robust CD4+ and CD8+ T cell-mediated anti-tumor immune responses involving both MHC-I and II [276].